ArticleAddiction science & clinical practice2026
Buprenorphine initiation from fentanyl using low-dose intramuscular ketamine: a pilot study.
Article in Addiction science & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBuprenorphine is an effective medication for treating opioid use disorder but is underutilized partly due to patient apprehensiveness of the severe withdrawal symptoms it can induce when started, particularly by fentanyl-dependent individuals. An emerging facilitator to buprenorphine initiation is ketamine, a dissociative anesthetic shown to reverse opioid withdrawal symptoms in case reports and small series. A 24-hour behavioral health crisis center implemented a quality improvement protocol to address difficulties transitioning patients from fentanyl to buprenorphine using a high-dose buprenorphine initiation strategy premedicated with a low, sub-dissociative dose of intramuscular ketamine.
methodsCrisis center personnel injected ketamine 10 mg intramuscularly at a cost of $0.44 per patient and 30 minutes later administered buprenorphine 8 mg sublingually to patients who self-reported recent use of fentanyl and were in at least moderate withdrawal. They assessed Clinical Opiate Withdrawal Scale (COWS) scores at baseline, 30 minutes after ketamine, and 30 minutes after buprenorphine. They compared length of stay (LOS) between patients initiating buprenorphine before and after implementing the protocol. They recorded pharmacy dispensing of buprenorphine prescriptions and follow-up visits within 30 days.
resultsIn 50 patients treated over 13 months, average COWS score dropped from 13.6 (range 8–21, SD 2.9) at baseline to 6.2 (range 0–17, SD 3.6) 30 minutes after ketamine and 4.1 (range 0–18, SD 4.0) 30 minutes after buprenorphine. Both decreases were statistically significant (p < 0.001) with very large effect sizes. Of the 50 patients, 36 (72%) experienced a decrease in COWS score including 27/50 (54%) with COWS score 0–3 by 30 minutes after buprenorphine. After protocol implementation, median LOS decreased from 66.0 hours (range 20–135) in the pre-protocol comparison sample to 7.0 hours (range 2–148) in the post-protocol sample. Patients reported no adverse effects of ketamine.
conclusionsIn this observational study, sub-dissociative dose intramuscular ketamine was a well-tolerated and inexpensive premedication for a high-dose buprenorphine initiation strategy. Most patients had rapid reduction in signs of fentanyl withdrawal after ketamine, and half had nearly complete resolution following buprenorphine. Ketamine may be a useful adjunct to increase buprenorphine uptake and reduce overdose deaths. Prospective research is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.